These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24136086)

  • 1. Disposition and metabolism of safinamide, a novel drug for Parkinson's disease, in healthy male volunteers.
    Leuratti C; Sardina M; Ventura P; Assandri A; Müller M; Brunner M
    Pharmacology; 2013; 92(3-4):207-16. PubMed ID: 24136086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers.
    Bauer M; Bliesath H; Leuratti C; Lackner E; Dieterle W; Müller M; Brunner M
    Pharmacology; 2010; 86(5-6):297-305. PubMed ID: 21071997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
    Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
    Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketoconazole treatment on the pharmacokinetics of safinamide and its plasma metabolites in healthy adult subjects.
    Krösser S; Marquet A; Gallemann D; Wolna P; Fauchoux N; Hermann R; Johne A
    Biopharm Drug Dispos; 2012 Dec; 33(9):550-9. PubMed ID: 23097240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safinamide for the treatment of Parkinson's disease.
    Dézsi L; Vécsei L
    Expert Opin Investig Drugs; 2014 May; 23(5):729-42. PubMed ID: 24650154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial.
    Marquet A; Kupas K; Johne A; Astruc B; Patat A; Krösser S; Kovar A
    Clin Pharmacol Ther; 2012 Oct; 92(4):450-7. PubMed ID: 22948897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
    Riska P; Lamson M; MacGregor T; Sabo J; Hattox S; Pav J; Keirns J
    Drug Metab Dispos; 1999 Aug; 27(8):895-901. PubMed ID: 10421616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
    Stocchi F; Torti M
    Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expert opinion on safinamide in Parkinson's disease.
    Onofrj M; Bonanni L; Thomas A
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.
    Müller T; Foley P
    Clin Pharmacokinet; 2017 Mar; 56(3):251-261. PubMed ID: 27665574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of safinamide for the drug portfolio of Parkinson's disease therapy.
    Müller T
    Expert Rev Neurother; 2013 Sep; 13(9):969-77. PubMed ID: 24053341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological disposition and metabolic fate of a new antiarrhythmic agent, alpha, alpha-dimethyl-4-(alpha, alpha, beta, beta-tetrafluorophenethyl) benzylamine in the rat, dog, monkey, baboon, and man.
    Zacchei AG; Weidner LL; Besselaar GH; Raftery EB
    Drug Metab Dispos; 1976; 4(4):387-401. PubMed ID: 8295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers.
    Jing S; Yuan Y; Leuratti C; Vaja V; Cattaneo C
    Clin Pharmacol Drug Dev; 2023 Nov; 12(11):1104-1113. PubMed ID: 37293981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.